<table id="table7" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>Table 7. Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction</caption>
<col align="left" width="20%"></col>
<col align="left" width="20%"></col>
<col align="left" width="60%"></col>
<thead>
<tr><th stylecode="Lrule" valign="top">Concomitant<br/>Drug Class:<br/>Drug Name</th><th stylecode="Lrule">Effect on Concentration of delavirdine or Concomitant Drug</th><th stylecode="Lrule Rrule" valign="top">Clinical Comment</th></tr>
</thead>
<tfoot>
<tr><td>↑ Indicates increase</td></tr>
<tr><td>↓ Indicates decrease</td></tr>
</tfoot>
<tbody>
<tr><td colspan="3" stylecode="Lrule Rrule" valign="top"><content stylecode="italics bold">HIV-Antiviral Agents</content></td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Amprenavir</td><td stylecode="Lrule Toprule" valign="top">↑ Amprenavir</td><td stylecode="Lrule Toprule Rrule" valign="top">Appropriate doses of this combination, with respect to safety, efficacy and pharmacokinetics, have not been established.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Didanosine<footnote id="Footnote10_10">See <content stylecode="bold"><linkhtml href="#clinical_pharmacology">CLINICAL PHARMACOLOGY</linkhtml></content> for magnitude of interaction, Tables 1 and 2.</footnote></td><td stylecode="Lrule Toprule" valign="top">↓ Delavirdine<br/>↓ Didanosine</td><td stylecode="Lrule Toprule Rrule" valign="top">Administration of didanosine (buffered tablets) and RESCRIPTOR should be separated by at least one hour.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Indinavir<footnoteref idref="Footnote10_10"></footnoteref></td><td stylecode="Lrule Toprule" valign="top">↑ Indinavir</td><td stylecode="Lrule Toprule Rrule" valign="top">A dose reduction of indinavir to 600 mg tid should be considered when RESCRIPTOR and indinavir are coadministered.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Lopinavir/Ritonavir</td><td stylecode="Lrule Toprule" valign="top">↑ Lopinavir<br/>↑ Ritonavir</td><td stylecode="Lrule Toprule Rrule" valign="top">Appropriate doses of this combination, with respect to safety, efficacy and pharmacokinetics, have not been established.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Nelfinavir<footnoteref idref="Footnote10_10"></footnoteref></td><td stylecode="Lrule Toprule" valign="top">↑ Nelfinavir<br/>↓ Delavirdine</td><td stylecode="Lrule Toprule Rrule" valign="top">Appropriate doses of this combination, with respect to safety, efficacy and pharmacokinetics, have not been established. (See <content stylecode="bold"><linkhtml href="#table1">CLINICAL PHARMACOLOGY: Tables 1</linkhtml> and <linkhtml href="#table2">2</linkhtml></content>.)</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Ritonavir</td><td stylecode="Lrule Toprule" valign="top">↑Ritonavir</td><td stylecode="Lrule Toprule Rrule" valign="top">Appropriate doses of this combination, with respect to safety, efficacy and pharmacokinetics, have not been established.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Saquinavir<footnoteref idref="Footnote10_10"></footnoteref></td><td stylecode="Lrule Toprule" valign="top">↑ Saquinavir</td><td stylecode="Lrule Toprule Rrule" valign="top">A dose reduction of saquinavir (soft gelatin capsules) may be considered when RESCRIPTOR and saquinavir are coadministered. (See <content stylecode="bold"><linkhtml href="#table1">CLINICAL PHARMACOLOGY: Table 1</linkhtml></content>.) Appropriate doses with respect to safety, efficacy and pharmacokinetics, have not been established.</td></tr>
<tr><td colspan="3" stylecode="Lrule Toprule Rrule" valign="top"><content stylecode="italics bold">Other Agents</content></td></tr>
<tr><td rowspan="2" stylecode="Lrule Toprule" valign="top">Acid blockers:<br/>  antacids<footnoteref idref="Footnote10_10"></footnoteref><br/><br/>H<sub>2</sub>Receptor antagonists:<br/>  cimetidine, famotidine,   nizatidine, ranitidine<br/>Proton pump inhibitors:<br/>  omeprazole, lansoprazole</td><td rowspan="2" stylecode="Lrule Toprule" valign="top">↓ Delavirdine</td><td stylecode="Lrule Toprule Rrule" valign="top">Doses of an antacid and RESCRIPTOR should be separated by at least one hour, because the absorption of delavirdine is reduced when coadministered with antacids.</td></tr>
<tr><td stylecode="Lrule Toprule Rrule" valign="top">These agents increase gastric pH and may reduce the absorption of delavirdine. Although the effect of these drugs on delavirdine absorption has not been evaluated, chronic use of these drugs with RESCRIPTOR is not recommended.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Amphetamines</td><td stylecode="Lrule Toprule" valign="top">↑ Amphetamines</td><td stylecode="Lrule Toprule Rrule" valign="top">Use with caution.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Antidepressant: <br/>trazodone</td><td stylecode="Lrule Toprule" valign="top">↑ trazodone</td><td stylecode="Lrule Toprule Rrule" valign="top">Concomitant use of trazodone and RESCRIPTOR may increase plasma concentrations of trazodone.  Adverse events of nausea, dizziness, hypotension and syncope have been observed following coadministration of trazodone and ritonavir.  If trazodone is used with a CYP3A4 inhibitor such as RESCRIPTOR, the combination should be used with caution and a lower dose of trazadone should be considered.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Antiarrhythmics:<br/>bepridil</td><td stylecode="Lrule Toprule" valign="top">↑ Antiarrhythmics</td><td stylecode="Lrule Toprule Rrule" valign="top">Use with caution. Increased bepridil exposure may be associated with life-threatening reactions such as cardiac  arrhythmias.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Amiodarone, lidocaine (systemic), quinidine, flecainide, propafenone</td><td stylecode="Lrule Toprule" valign="top"></td><td stylecode="Lrule Toprule Rrule" valign="top">Caution is warranted and therapeutic concentration monitoring is recommended, if available, for antiarrhythmics when coadministered with RESCRIPTOR.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Anticoagulant:<br/> warfarin</td><td stylecode="Lrule Toprule" valign="top">↑ Warfarin</td><td stylecode="Lrule Toprule Rrule" valign="top">It is recommended that INR (international normalized ratio) be monitored.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Anti-infective: <br/>clarithromycin<footnoteref idref="Footnote10_10"></footnoteref></td><td stylecode="Lrule Toprule" valign="top">↑ Clarithromycin</td><td stylecode="Lrule Toprule Rrule" valign="top">When coadministered with RESCRIPTOR, clarithromycin should be adjusted in patients with impaired renal function:	<list listtype="unordered"><item>For patients with CL<sub>CR</sub> 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%.</item><item>For patients with CL<sub>CR</sub>&lt;30 mL/min the dose of clarithromycin should be reduced by 75%.</item></list></td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Calcium channel blockers:<br/>amlodipine, diltiazem, felodipine, isradipine, nifedipine, nicardipine, nimodipine, nisoldipine, verapamil</td><td stylecode="Lrule Toprule" valign="top">↑ Calcium channel blockers</td><td stylecode="Lrule Toprule Rrule" valign="top">Caution is warranted and clinical monitoring of patients is recommended.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Corticosteroid:<br/>dexamethasone</td><td stylecode="Lrule Toprule" valign="top">↓ Delavirdine</td><td stylecode="Lrule Toprule Rrule" valign="top">Use with caution. RESCRIPTOR may be less effective due to decreased delavirdine plasma concentrations in patients taking these agents concomitantly.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Erectile dysfunction agents:<br/>  sildenafil</td><td stylecode="Lrule Toprule" valign="top">↑ Sildenafil</td><td stylecode="Lrule Toprule Rrule" valign="top">Sildenafil should not exceed a maximum single dose of 25 mg in a 48-hour period.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">HMG-CoA reductase inhibitors:<br/>  atorvastatin, cerivastatin, fluvastatin</td><td stylecode="Lrule Toprule" valign="top">↑ Atorvastatin<br/>↑ Cerivastatin<br/>↑ Fluvastatin</td><td stylecode="Lrule Toprule Rrule" valign="top">Use lowest possible dose of atorvastatin or cerivastatin, or fluvastatin with careful monitoring, or consider other HMG-CoA reductase inhibitors such as pravastatin in combination with RESCRIPTOR.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Immunosuppressants:<br/>  cyclosporine, tacrolimus, rapamycin</td><td stylecode="Lrule Toprule" valign="top">↑ Immunosuppressants</td><td stylecode="Lrule Toprule Rrule" valign="top">Therapeutic concentration monitoring is recommended for immunosuppressant agents when coadministered with RESCRIPTOR.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Inhaled/nasal steroid: <br/>Fluticasone</td><td stylecode="Lrule Toprule" valign="top">↑ fluticasone</td><td stylecode="Lrule Toprule Rrule" valign="top">Concomitant use of fluticasone propionate and RESCRIPTOR may increase plasma concentrations of fluticasone propionate. Use with caution. Consider alternatives to fluticasone propionate, particularly for long-term use.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Narcotic analgesic:<br/>methadone</td><td stylecode="Lrule Toprule" valign="top">↑ Methadone</td><td stylecode="Lrule Toprule Rrule" valign="top">Dosage of methadone may need to be decreased when coadministered with RESCRIPTOR.</td></tr>
<tr><td stylecode="Lrule Toprule" valign="top">Oral contraceptives:<br/> ethinyl estradiol</td><td stylecode="Lrule Toprule" valign="top">↑ Ethinyl estradiol</td><td stylecode="Lrule Toprule Rrule" valign="top">Concentrations of ethinyl estradiol may increase. However, the clinical significance is unknown.</td></tr>
</tbody>
</table>